Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Jiaxin Niu"'
Publikováno v:
Current Oncology Reports. 23
Both anti-angiogenesis and immunotherapy are well-established therapeutic options in solid tumors. Here, we review the rationale as well as clinical evidence of combining these two approaches. There is strong rationale and substantial preclinical and
Autor:
Jessica M. Frakes, Yun Hu, Juliette Thariat, Tanguy Y. Seiwert, Jiaxin Niu, Maria Angelica Cortez, Ping Zhang, K. Jameson, Sylvie Bonvalot, Sébastien Paris, Colette J. Shen, James W. Welsh, Zsuzsanna Papai, Jimmy J. Caudell, Jared Weiss, Hampartsoum B. Barsoumian, P. Said
Publikováno v:
Journal of Clinical Oncology. 39:2591-2591
2591 Background: Despite recent advances, resistance to immune checkpoint inhibitors (ICI), observed in over 80% of treated patients, is currently the main challenge in immuno-oncology. Intense efforts are being made to identify combination therapies
Autor:
Jessica M. Frakes, Jiaxin Niu, Jared Weiss, Tanguy Y. Seiwert, P. Said, Jimmy J. Caudell, Colette J. Shen, K. Jameson, Ari Rosenberg
Publikováno v:
Journal of Clinical Oncology. 39:2590-2590
2590 Background: Immune checkpoint inhibitors (ICIs) targeting PD-1 are an effective treatment for a variety of cancers. However, the majority of patients (pts) exhibit resistance to ICIs. Overcoming this resistance represents a major challenge in im